Basal metabolic rate in children with chronic kidney disease and healthy control children

Caroline E Anderson1, Rodney D Gilbert2, Marinos Elia3

  • 1Department of Nutrition and Dietetics, NIHR Southampton Biomedical Research Centre-Nutrition, Southampton Children's Hospital, University of Southampton-University Hospital Southampton NHS Foundation Trust, E level Tremona Road, Southampton, SO16 6YD, UK. caroline.anderson@uhs.nhs.uk.

Insights

Children with chronic kidney disease (CKD) have similar basal metabolic rates (BMR) to healthy peers. However, lower kidney function in children with CKD correlates with reduced BMR, impacting energy needs.

Area of Science:

  • Pediatric Nephrology
  • Human Physiology
  • Nutritional Science

Background:

  • Meeting energy requirements is crucial for growth and outcomes in children with chronic kidney disease (CKD).
  • Limited published data exists on energy expenditure in pediatric CKD.
  • Basal metabolic rate (BMR), a key component of energy expenditure, was investigated in relation to kidney function.

Purpose of the Study:

  • To determine if basal metabolic rate (BMR) in children with chronic kidney disease (CKD) is related to kidney function.
  • To assess BMR independently of weight, height, and lean body mass (LBM).

Main Methods:

  • Compared BMR measured by indirect calorimetry in 20 children with CKD and 20 healthy controls.
  • Predicted BMR using the Schofield equation.
  • Related estimated glomerular filtration rate (eGFR) to BMR, adjusting for weight, height, age, and LBM.

Main Results:

  • Adjusted BMR did not significantly differ between children with CKD and healthy controls.
  • Percentage of predicted BMR was also comparable between the groups.
  • Within the CKD group, eGFR showed a significant positive relationship with BMR, independent of nutritional status and LBM.

Conclusions:

  • Estimated average requirement can guide energy prescriptions for children with moderate CKD (stage 3).
  • Children with more severe CKD exhibited significantly lower metabolic rates.
  • Individualized assessment of energy needs may be necessary for pediatric CKD patients.
Abstract

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
315
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
356
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.0K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
645
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
353